Back to Browse Journals » Clinical Interventions in Aging » Volume 2 » Issue 4

The many faces of testosterone

Authors Jerald Bain

Published 15 January 2008 Volume 2007:2(4) Pages 567—576

DOI http://dx.doi.org/10.2147/CIA.S1417

Jerald Bain

Department of Medicine, Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; Division of Endocrinology and Metabolism, Mount Sinai Hospital, Toronto, Ontario, Canada

Abstract: Testosterone is more than a “male sex hormone”. It is an important contributor to the robust metabolic functioning of multiple bodily systems. The abuse of anabolic steroids by athletes over the years has been one of the major detractors from the investigation and treatment of clinical states that could be caused by or related to male hypogonadism. The unwarranted fear that testosterone therapy would induce prostate cancer has also deterred physicians form pursuing more aggressively the possibility of hypogonadism in symptomatic male patients. In addition to these two mythologies, many physicians believe that testosterone is bad for the male heart. The classical anabolic agents, 17-alkylated steroids, are, indeed, potentially harmful to the liver, to insulin action to lipid metabolism. These substances, however, are not testosterone, which has none of these adverse effects. The current evidence, in fact, strongly suggests that testosterone may be cardioprotective. There is virtually no evidence to implicate testosterone as a cause of prostate cancer. It may exacerbate an existing prostate cancer, although the evidence is flimsy, but it does not likely cause the cancer in the first place. Testosterone has stimulatory effects on bones, muscles, erythropoietin, libido, mood and cognition centres in the brain, penile erection. It is reduced in metabolic syndrome and diabetes and therapy with testosterone in these conditions may provide amelioration by lowering LDL cholesterol, blood sugar, glycated hemoglobin and insulin resistance. The best measure is bio-available testosterone which is the fraction of testosterone not bound to sex hormone binding globulin. Several forms of testosterone administration are available making compliance much less of an issue with testosterone replacement therapy.
Keywords: testosterone, androgens, male hypogonadism, anabolic steroids

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Effects of 5-aminolevulinic acid-mediated sonodynamic therapy on macrophages

Cheng J, Sun X, Guo S, Cao W, Chen H, Jin Y, Li B, Li Q, Wang H, Wang Z, Zhou Q, Wang P, Zhang Z, Cao W, Tian Y

International Journal of Nanomedicine 2013, 8:669-676

Published Date: 13 February 2013

Correcting magnesium deficiencies may prolong life

Rowe WJ

Clinical Interventions in Aging 2012, 7:51-54

Published Date: 16 February 2012

Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST)

Hauber AB, Gonzalez JM, Coombs J, Sirulnik A, Palacios D, Scherzer NJ

Patient Preference and Adherence 2011, 5:307-314

Published Date: 24 June 2011

Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage

Nancy Kunjukunju, Christine R Gonzales, William S Rodden

Clinical Ophthalmology 2011, 5:155-157

Published Date: 4 February 2011

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Juan V Llau, Raquel Ferrandis, Pilar Sierra, et al

Vascular Health and Risk Management 2010, 6:855-867

Published Date: 29 September 2010

Role of paliperidone extended-release in treatment of schizoaffective disorder

Carla M Canuso, Ibrahim Turkoz, Dong Jing Fu, et al

Neuropsychiatric Disease and Treatment 2010, 6:667-679

Published Date: 28 September 2010

Cardiac risk stratification: Role of the coronary calcium score

Rakesh K Sharma, Rajiv K Sharma, Donald J Voelker, et al

Vascular Health and Risk Management 2010, 6:603-611

Published Date: 14 July 2010

Epidemiologic characteristics and risk factors for renal cell cancer

Loren Lipworth, Robert E Tarone, Lars Lund, Joseph K McLaughlin

Clinical Epidemiology 2009, 1:33-43

Published Date: 3 April 2009

The characteristics of keratomycosis by Beauveria bassiana and its successful treatment with antimycotic agents

Hiroko Sonoyama, Kaoru Araki-Sasaki, Shigeyasu Kazama, Tsutomu Kawasaki, Hidenao Ideta, et al

Clinical Ophthalmology 2008, 2:675-678

Published Date: 12 September 2008